Clinical Oncology: Case Reports

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Case Report, Clin Oncol Case Rep Vol: 5 Issue: 7

EDP Protocol For Metastatic Inoperable Pheochromocytoma: A Case Report

Shwartz L1, Gafter-Gvili A1, Buchrits S1, Goshen S1, Halperin E1*

1Department of Internal Medicine A, Rabin Medical Center, Beilinson Hospital, Petah-Tikva, Israel, 2 Sackler Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel

*Corresponding Author: Erez Halperin
Department of Internal Medicine A, Beilinson Campus, Rabin Medical centre, Israel

Received: June 30, 2022; Manuscript No: COCR-22-68207;
Editor Assigned: July 02, 2022; PreQC Id: COCR-22-68207 (PQ);
Reviewed: July 17, 2022; QC No: COCR-22-68207 (Q);
Revised: July 19, 2022; Manuscript No: COCR-22- 68207 (R);
Published: July 28, 2022; DOI: 10.4172/cocr.5(7).240

Citation: Shwartz L, et al. (2022) EDP Protocol For Metastatic Inoperable Pheochromocytoma: A Case Report. Clin Oncol Case Rep 5:7


Introduction: Pheochromocytoma and Paraganglioma (PPGLs) are rare neuroendocrine tumors which are known for their excessive catecholamines secretion and their variable clinical presentation. The majority of PPGLs are benign. As such, therapeutic options for the treatment of metastatic pheochromocytoma are limited, especially when complete respectability is impossible. Moreover, the acceptable chemotherapy regimen doesn’t affect overall survival of these patients. We report a case of a patient with neurofibromatosis type 1 and inoperable metastatic pheochromocytoma, treated with a chemotherapy protocol derived from the treatment of adrenocortical carcinoma and the partial response seen to this treatment.   

Case presentation: 48-year-old caucasian woman with a history of neurofibromatosis type 1 presented with epigastric pain, dry mouth, and hypertension. Her blood work revealed elevated Aminotransferases levels (AST=53 U/L, ALT=91 U/L), Serum Alkaline Phosphatase (ALP) levels and Gamma-Glutamyl Transferase (GGT) levels (ALKP=188 U/L ,GGT=250 U/L) with high levels of lactate dehydrogenase (LDH= 797 U/L). An abdominal-pelvic ultrasonography demonstrated 8.9 cm X 8 cm X7 cm adrenal mass with possible liver metastases. Chest-abdomen-pelvis contrast enhanced Computed Tomography (CT) revealed space occupying lesion in the right adrenal, penetrating the inferior vena cava, and involving the right kidney, the left and right renal veins, and the aorta. Liver metastases were observed as well. Urine normetanephrine was 7173.5 mcg/24-hours, Normetanephrine/ creatinine ratio was 6676 and metanephrine/creatinine ratio was 225. A presumptive diagnosis of metastatic pheochromocytoma was made and subsequently validated in histopathology of a liver biopsy. Due to the proximity of the tumor to large vessels, debulking procedure couldn’t be performed.  She received 6 cycles of chemotherapy protocol used for the treatment of ACC- etoposide, doxorubicin, and cisplatin (EDP regimen). Follow-up urine normetanephrine decreased to 390 mcg/24-hour and the patient's symptoms relieved. In a 68Ga-DOTATATE positron emission tomographic scan, both the right adrenal mass and the diffused liver metastases had shrunk. However, the patient's death was determined only four months after the diagnosis, due to internal bleeding.

Conclusions: To the best of our knowledge, this is the first reported case of metastatic pheochromocytoma that showed a partial response to ACC chemotherapy regimen. This case raises the possibility that other chemotherapy regimens then CVD, merit further investigation in the setting of metastatic pheochromocytoma.

Keywords: Metastatic pheochromocytoma; CVD chemotherapy; EDP chemotherapy; Neurofibromatosis type 1; PPGL

international publisher, scitechnol, subscription journals, subscription, international, publisher, science

Track Your Manuscript

Awards Nomination

open access